Please login to the form below

Not currently logged in
Email:
Password:

New CEO for Grayling Germany

Frank Schönrock joins from Grünenthal
grayling Frank Schonrock

Frank Schönrock has left his role at pharma company Grünenthal to join the med comms agency Grayling Germany as CEO.

Schönrock joined Grünenthal in 2011 as VP of corporate communications before moving onto a global external communications role in his last year at the company. He was also a member of Grünenthal's global group leadership committee.

He now heads the German division of global comms network Grayling, overseeing a team of 40 consultants in Frankfurt, Düsseldorf and Hamburg.

Schönrock has previous agency experience having spent 12 year at Edelman Germany in several management positions, including co-heading the firms' office in Frankfurt.

“Frank is an exceptional talent and we are very proud to have him on board,” said Jan Simunek, Grayling's regional director for the DACH region, Central & Eastern Europe, Russia and CIS

“His background in healthcare, financial services, issues & crisis management and litigation PR will be particularly valuable as we look to grow the firm in Germany over the months and years to come.”

6th November 2014

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics